Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Long-Term Remission (>3 years) after Rituximab Monotherapy Used for Patients with Relapsed Indolent Non-Hodgkin Lymphomas (NHL)

Anne-Sophie Michallet, MD PhD, Florence Beckerich, Fadhela Bouafia-Sauvy, Daniel Espinouse, MD, Gilles Salles, MDPhD, Bertrand Coiffier, MD PhD

Blood (2014) 124 (21): 1709.

https://doi.org/10.1182/blood.V124.21.1709.1709

Published: 2014

Journal Articles

A Randomized Phase II Study Evaluating the Efficacy, Safety and Cost-Effectiveness of Pegfilgrastim and Filgrastim After High Dose Chemotherapy and Autologous Stem Cell Transplantation In Patients with Lymphoma and Myeloma (PALM Study).

Catherine Sebban, MD, Anne Lefranc, MsC, Lionel Perrier, PhD, Philippe Moreau, MD, Daniel Espinouse, MD, Marie Pierre Moles-Moreau, MD, Leila Kammoun, MD, Herve Ghesquieres, MD, Celine Segura-Ferlay, MsC, Jacques-Olivier Bay, MD, PhD, Severine Lissandre, MD, David Pérol, MD, Mauricette Michallet, MD, Philippe Quittet, MD

Blood (2010) 116 (21): 3479.

https://doi.org/10.1182/blood.V116.21.3479.3479

Published: 2010

Journal Articles

Maintenance Alemtuzumab in Refractory B-Cell Chronic Lymphocytic Leukemia Patients: Updated Data.

Catherine Thieblemont, Roch Houot, Boubacari Ali Toure, Catherine Traulle, Anne-Sophie Michallet, Fadhela Bouafia, Daniel Espinouse, Gilles Salles, Bertrand Coiffier

Blood (2005) 106 (11): 5032.

https://doi.org/10.1182/blood.V106.11.5032.5032

Published: 2005

Journal Articles

Identification of a Rare e8a2 BCR-ABL Fusion Gene in Three Novel Chronic Myeloid Leukemia Patients Treated with Imatinib.

Jean-Michel Cayuela, Philippe Rousselot, Franck Nicolini, Daniel Espinouse, Christophe Ollagnier, M.H. Bui-Thi, Kaddour Chabane, E. Raffoux, Isabelle Tigaud, Jean-Pierre Magaud, Sandrine Hayette

Blood (2005) 106 (11): 4830.

https://doi.org/10.1182/blood.V106.11.4830.4830

Published: 2005

Journal Articles

High CD34 + Cell Counts Decrease Hematologic Toxicity of Autologous Peripheral Blood Progenitor Cell Transplantation

Nicolas Ketterer, Gilles Salles, Michel Raba, Daniel Espinouse, Anne Sonet, Pierre Tremisi, Charles Dumontet, Isabelle Moullet, Assia Eljaafari-Corbin, Eve-Marie Neidhardt-Berard, Fadhela Bouafia, Bertrand Coiffier

Blood (1998) 91 (9): 3148–3155.

https://doi.org/10.1182/blood.V91.9.3148

Published: 1998

NARROW

Long-Term Remission (>3 years) after Rituximab Monotherapy Used for Patients with Relapsed Indolent Non-Hodgkin Lymphomas (NHL)

A Randomized Phase II Study Evaluating the Efficacy, Safety and Cost-Effectiveness of Pegfilgrastim and Filgrastim After High Dose Chemotherapy and Autologous Stem Cell Transplantation In Patients with Lymphoma and Myeloma (PALM Study).

Maintenance Alemtuzumab in Refractory B-Cell Chronic Lymphocytic Leukemia Patients: Updated Data.

Identification of a Rare e8a2 BCR-ABL Fusion Gene in Three Novel Chronic Myeloid Leukemia Patients Treated with Imatinib.

High CD34 + Cell Counts Decrease Hematologic Toxicity of Autologous Peripheral Blood Progenitor Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Long-Term Remission (>3 years) after Rituximab Monotherapy Used for Patients with Relapsed Indolent Non-Hodgkin Lymphomas (NHL)

A Randomized Phase II Study Evaluating the Efficacy, Safety and Cost-Effectiveness of Pegfilgrastim and Filgrastim After High Dose Chemotherapy and Autologous Stem Cell Transplantation In Patients with Lymphoma and Myeloma (PALM Study).

Maintenance Alemtuzumab in Refractory B-Cell Chronic Lymphocytic Leukemia Patients: Updated Data.

Identification of a Rare e8a2 BCR-ABL Fusion Gene in Three Novel Chronic Myeloid Leukemia Patients Treated with Imatinib.

High CD34 + Cell Counts Decrease Hematologic Toxicity of Autologous Peripheral Blood Progenitor Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only